XML 51 R38.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

SPONSORED RESEARCH AND LICENSE AGREEMENTS AND GOVERNMENT CONTRACT (Details) $ in Thousands | 1 Months Ended | 3 Months Ended | 6 Months Ended | 7 Months Ended | 11 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | --- | --- | ---
Aug. 31, 2023 USD ($) | Jul. 27, 2022 USD ($) | Apr. 30, 2021 USD ($) | Feb. 29, 2020 USD ($) | Oct. 31, 2019 USD ($) agreement | Jan. 31, 2019 USD ($) | Oct. 31, 2018 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2023 USD ($) | Dec. 31, 2022 USD ($) | Jun. 30, 2022 USD ($) | Mar. 31, 2021 USD ($) | Jun. 30, 2024 USD ($) period | Jun. 30, 2023 USD ($) | Jun. 30, 2024 USD ($) | Jun. 30, 2024 USD ($) | Dec. 31, 2021 USD ($) | Jan. 31, 2024 USD ($) | Dec. 31, 2023 USD ($)
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payments |  |  |  |  |  |  |  |  |  |  |  |  | $ 1,300,000 |  |  |  |  |  |
Right to opt out of agreement, different specified times | period |  |  |  |  |  |  |  |  |  |  |  |  | 2 |  |  |  |  |  |
Upfront payment received |  |  | $ 125,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Payment of cost share to collaboration partner |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,605 | $ 1,754 |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  | $ 20,000 |  |  |  |  |  |  |  |  |
Accounts receivable |  |  |  |  |  |  |  | $ 28,904 |  |  |  |  | 28,904 |  | $ 28,904 | $ 28,904 |  |  | $ 30,550
Intangible asset |  |  |  |  |  |  |  | 28,275 |  |  |  |  | 28,275 |  | 28,275 | 28,275 |  |  | 13,878
Accounts payable |  |  |  |  |  |  |  | 6,130 |  |  |  |  | 6,130 |  | 6,130 | 6,130 |  |  | 7,142
Amortization of intangible assets |  |  |  |  |  |  |  | 600 | $ 300 |  |  |  | 1,000 | 500 |  |  |  |  |
Specified Development Events |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payments |  |  |  |  |  |  |  |  |  |  |  |  | 279,500 |  |  |  |  |  |
Specified Regulatory Events |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payments |  |  |  |  |  |  |  |  |  |  |  |  | 263,100 |  |  |  |  |  |
Specified Product Launch Events |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payments |  |  |  |  |  |  |  |  |  |  |  |  | 796,000 |  |  |  |  |  |
Development and regulatory milestones by non-CNS disease products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payments |  |  |  |  |  |  |  |  |  |  |  |  | 330,000 |  |  |  |  |  |
Development and regulatory milestones by non-CNS disease products | Milestone payments on a product-by-product basis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payments |  |  |  |  |  |  |  |  |  |  |  |  | 100,000 |  |  |  |  |  |
Development and regulatory milestones by CNS disease products |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payments |  |  |  |  |  |  |  |  |  |  |  |  | 255,000 |  |  |  |  |  |
Development and regulatory milestones by CNS disease products | Milestone payments on a product-by-product basis |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payments |  |  |  |  |  |  |  |  |  |  |  |  | 150,000 |  |  |  |  |  |
Grifols |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  | $ 30,000 |  |  |  |  |  |  |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | 0 |  |  |  |  | 0 |  | 0 | 0 |  |  | 0
Grifols | Delivery of drug supply for commercialization |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  | 0 | 1,200 |  |  |  | 0 | 2,800 |  |  |  |  |
Grifols | Commercial milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payments |  |  |  |  |  | $ 297,500 |  |  |  |  |  |  |  |  |  |  |  |  |
Kissei |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payments |  |  |  |  |  |  | $ 147,000 |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  | $ 33,000 |  |  |  |  |  |  |  |  |  |  |  |
Knight | Commercial and license agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  |  |  |  |  |  |  |  |  | 2,000 |  |  |  |  |  |
Knight | Maximum | Commercial milestones | Commercial and license agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payments |  |  |  |  |  |  |  |  |  |  |  |  | 20,000 |  |  |  |  |  |
Forma | Commercial milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential payments |  | $ 165,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Forma | Development and regulatory milestones |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential payments |  | $ 67,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
fostamatinib | Grifols |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative payment received |  |  |  | $ 20,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
fostamatinib | Grifols | Upon EMA approval of fostamatinib for treatment of chronic ITP |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Contingent payments |  |  |  | 17,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
fostamatinib | Grifols | Creditable advance royalty payment |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborative payment received |  |  |  | $ 2,500 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
fostamatinib | Grifols | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Royalty payment as a percentage of net sales |  |  |  |  |  | 30.00% |  |  |  |  |  |  |  |  |  |  |  |  |
fostamatinib | Kissei |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  | 2,200 | 0 |  |  |  | 4,500 | 0 |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | 1,400 |  |  |  |  | 1,400 |  | 1,400 | 1,400 |  |  | 1,400
Revenue recognized associated with remaining performance obligation |  |  |  |  |  |  |  | 0 | 0 |  |  |  | 0 | 0 |  |  |  |  |
Collaborative payment received |  |  |  |  |  |  |  |  |  |  | $ 5,000 |  |  |  |  |  |  |  |
Accounts receivable |  |  |  |  |  |  |  |  |  | 20,000 |  |  |  |  |  |  |  |  |
fostamatinib | Medison |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  | 100 |  |  |  |  | 200 |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | 0 |  |  |  |  | $ 0 |  | 0 | 0 |  |  | 0
fostamatinib | Medison | Commercial and license agreements |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Upfront payment received |  |  |  |  | $ 5,000 |  |  |  |  |  |  |  |  |  |  |  |  |  |
Option to buy back product rights within number of months from regulatory approval |  |  |  |  |  |  |  |  |  |  |  |  | 6 months |  |  |  |  |  |
Number of agreements | agreement |  |  |  |  | 2 |  |  |  |  |  |  |  |  |  |  |  |  |  |
fostamatinib | BARDA |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  | 0 |  |  |  |  | $ 0 |  |  | 100 |  |  |
fostamatinib | BARDA | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Potential payments | $ 800 |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
ocadusertib |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Company's percentage of development costs |  |  |  |  |  |  |  |  |  |  |  |  | 20.00% |  |  |  |  |  |
Financing component liability |  |  |  |  |  |  |  | 57,900 |  |  |  |  | $ 57,900 |  | 57,900 | 57,900 |  |  |
Financing liability interest accretion discount rate |  |  |  |  |  |  |  |  |  |  |  |  | 6.40% |  |  |  |  |  |
Financing liability with accreted interest expense |  |  |  |  |  |  |  | 40,000 |  |  |  |  | $ 40,000 |  | 40,000 | 40,000 |  |  | 43,600
Accretion expense |  |  |  |  |  |  |  | 0 | 0 |  |  |  | 0 | 0 |  |  |  |  |
Development costs due to collaboration partner |  |  |  |  |  |  |  | 21,400 |  |  |  |  | 21,400 |  | 21,400 | 21,400 |  |  |
Revenue, remaining performance obligation |  |  |  |  |  |  |  |  |  |  |  | $ 67,100 |  |  |  |  |  |  |
Deferred revenue |  |  |  |  |  |  |  | 0 |  |  |  |  | 0 |  | 0 | 0 |  |  | 0
ocadusertib | Amended Lilly Agreement |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Funding commitment |  |  |  |  |  |  |  | 22,600 |  |  |  |  | $ 22,600 |  | 22,600 | 22,600 |  |  |
Right to opt-back-in co-funding of R552 development, term |  |  |  |  |  |  |  |  |  |  |  |  | 30 days |  |  |  |  |  |
ocadusertib | Maximum |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Funding commitment |  |  |  |  |  |  |  | 65,000 |  |  |  |  | $ 65,000 |  | 65,000 | $ 65,000 |  |  |
Non-CNS penetrant IP |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  | $ 60,400 |  |  |  |  |  |  |
CNS penetrant IP | Licensed Rights |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 6,700 |  |
Royalty | Grifols |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  | 1,100 | 800 |  |  |  | $ 2,200 | 1,500 |  |  |  |  |
REZLIDHIA | Strategic collaboration agreement with MDACC |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development costs due to collaboration partner |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 15,000
Payment of cost share to collaboration partner |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 2,000 |  |  |  |
Collaboration period |  |  |  |  |  |  |  |  |  |  |  |  | 5 years |  |  |  |  |  |
REZLIDHIA | Strategic collaboration agreement with CONNECT |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Development costs due to collaboration partner |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  | $ 3,000 |
Collaboration period |  |  |  |  |  |  |  |  |  |  |  |  | 4 years |  |  |  |  |  |
REZLIDHIA | Forma | FDA approval and first commercial sale of product |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Intangible asset |  |  |  |  |  |  |  |  |  | $ 15,000 |  |  |  |  |  |  |  |  |
Government contracts |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Collaborations |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Revenue recognized |  |  |  |  |  |  |  | $ 0 | $ 1,000 |  |  |  | $ 0 | $ 1,000 |  |  |  |  |

X
- Definition Option under agreement to buy back product rights within number of months from regulatory approval, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | rigl_AgreementOptionToBuyBackProductRightsWithinNumberOfMonthsFromRegulatoryApproval
Namespace Prefix: | rigl_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Period of time of collaboration, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | rigl_CollaborationTerm
Namespace Prefix: | rigl_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Maximum amount of contingent payments under collaborative arrangement. + References No definition available. + Details
Name: | rigl_CollaborativeArrangementPotentialPayments
Namespace Prefix: | rigl_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the revenue recognized during the period under the terms of sponsored research and license agreements. + References No definition available. + Details
Name: | rigl_CollaborativeArrangementRevenueRecognized
Namespace Prefix: | rigl_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the amount of upfront fees received during the period under the terms of collaborative and licensing agreement. + References No definition available. + Details
Name: | rigl_CollaborativeArrangementUpfrontFeeReceived
Namespace Prefix: | rigl_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents additional contingent payments by entities. + References No definition available. + Details
Name: | rigl_ContingentPaymentsUnderAgreement
Namespace Prefix: | rigl_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Percentage of development costs in cost sharing arrangement. + References No definition available. + Details
Name: | rigl_DevelopmentCostsCostSharingArrangementPercentage
Namespace Prefix: | rigl_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount due to collaboration partner. + References No definition available. + Details
Name: | rigl_DueToCollaborationPartner
Namespace Prefix: | rigl_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition The amount of financing liability including interest expense accretion. + References No definition available. + Details
Name: | rigl_FinancingLiabilityIncludingInterestExpenseAccretion
Namespace Prefix: | rigl_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Rate applied to the undiscounted amount of financing liability. + References No definition available. + Details
Name: | rigl_FinancingLiabilityInterestAccretionDiscountRate
Namespace Prefix: | rigl_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of agreements. + References No definition available. + Details
Name: | rigl_NumberOfAgreements
Namespace Prefix: | rigl_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Payment of cost share to collaboration partner. + References No definition available. + Details
Name: | rigl_PaymentOfCostShareToCollaborationPartner
Namespace Prefix: | rigl_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the period of time of right to opt-back-in co-funding, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. + References No definition available. + Details
Name: | rigl_RightToOptBackInCoFundingTerm
Namespace Prefix: | rigl_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents the number of periods with right to opt out of agreement. + References No definition available. + Details
Name: | rigl_RightToOptOutOfAgreementNumberOfPeriods
Namespace Prefix: | rigl_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Represents royalty payment as a percentage of net sales. + References No definition available. + Details
Name: | rigl_RoyaltyPaymentAsPercentageOfNetSales
Namespace Prefix: | rigl_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 852 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 10 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481372/852-10-55-10 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.19(a)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccountsPayableCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-2 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Topic 310 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 9 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481990/310-10-45-9 + Details
Name: | us-gaap_AccountsReceivableNetCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Amount recognized for the passage of time, typically for liabilities, that have been discounted to their net present values. Excludes accretion associated with asset retirement obligations. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 35 -Paragraph 4 -Publisher FASB -URI https://asc.fasb.org//1943274/2147481639/420-10-35-4 Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 420 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (b)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482017/420-10-50-1 + Details
Name: | us-gaap_AccretionExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The aggregate expense charged against earnings to allocate the cost of intangible assets (nonphysical assets not used in production) in a systematic and rational manner to the periods expected to benefit from such assets. As a noncash expense, this element is added back to net income when calculating cash provided by or used in operations using the indirect method. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 28 -Subparagraph (b) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-28 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 45 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482686/350-30-45-2 Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 350 -SubTopic 30 -Section 50 -Paragraph 2 -Subparagraph (a)(2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482665/350-30-50-2 + Details
Name: | us-gaap_AmortizationOfIntangibleAssets
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 606 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 8 -Subparagraph (b) -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-8 + Details
Name: | us-gaap_ContractWithCustomerLiabilityRevenueRecognized
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of deferred income and obligation to transfer product and service to customer for which consideration has been received or is receivable. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(26)(c)) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_DeferredRevenue
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance. + References No definition available. + Details
Name: | us-gaap_IntangibleAssetsNetIncludingGoodwill
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | instant

X
- Definition Minimum amount of other commitment not otherwise specified in the taxonomy. Excludes commitments explicitly modeled in the taxonomy, including but not limited to, long-term and short-term purchase commitments, recorded and unrecorded purchase obligations, supply commitments, registration payment arrangements, leases, debt, product warranties, guarantees, environmental remediation obligations, and pensions. + References No definition available. + Details
Name: | us-gaap_OtherCommitment
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Cash received from collaborators during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 230 -SubTopic 10 -Section 45 -Paragraph 25 -Subparagraph (a) -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_ProceedsFromCollaborators
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Recorded amount of the accrual for a material component of a product liability contingency. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 450 -SubTopic 20 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SAB Topic 5.Y.Q2) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480102/450-20-S99-1 + Details
Name: | us-gaap_ProductLiabilityAccrualComponentAmount
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of transaction price allocated to performance obligation that has not been recognized as revenue. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Name Accounting Standards Codification -Section 50 -Paragraph 13 -Subparagraph (a) -SubTopic 10 -Topic 606 -Publisher FASB -URI https://asc.fasb.org//1943274/2147479806/606-10-50-13 + Details
Name: | us-gaap_RevenueRemainingPerformanceObligation
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_SpecifiedDevelopmentEventsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_SpecifiedRegulatoryEventsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_SpecifiedProductLaunchEventsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByNonCentralNervousSystemDiseaseProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_StatementScenarioAxis=rigl_MilestonePaymentsOnProductByProductBasisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesByCentralNervousSystemDiseaseProductsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=rigl_GrifolsS.a.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_OneTimeDeliveryOfDrugSupplyForCommercializationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_SpecifiedCommercialMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=rigl_KisseiPharmaceuticalCo.Ltd.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=rigl_KnightTherapeuticsInternationalSaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rigl_CommercialAndLicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=rigl_FormaTherapeuticsHoldingsIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_DevelopmentAndRegulatoryMilestonesMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rigl_FostamatinibMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_EuropeanMedicinesAgencyApprovalOfFostamatinibForTreatmentOfChronicImmuneThrombocytopenicPurpuraMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_CreditableAdvanceRoyaltyPaymentMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=rigl_MedisonPharmaLtd.Member
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=rigl_BiomedicalAdvancedResearchAndDevelopmentAuthorityMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rigl_OcadusertibMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rigl_AmendedLillyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rigl_NonCentralNervousSystemPenetrantIntellectualPropertyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rigl_CentralNervousSystemPenetrantIntellectualPropertyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_LicensedRightsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=rigl_RezlidhiaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rigl_StrategicCollaborationAgreementWithMdaccMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=rigl_StrategicCollaborationAgreementWithConnectMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | rigl_AchievementOfMilestoneAxis=rigl_FdaApprovalAndFirstCommercialSaleOfProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_GovernmentContractMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |